EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
13.47
-0.13 (-0.96%)
Apr 28, 2026, 4:00 PM EDT - Market closed
EyePoint Revenue
In the year 2025, EyePoint had annual revenue of $31.37M, down -27.50%. EyePoint had revenue of $620.00K in the quarter ending December 31, 2025, a decrease of -94.65%.
Revenue (ttm)
$31.37M
Revenue Growth
-27.50%
P/S Ratio
35.82
Revenue / Employee
$146,593
Employees
214
Market Cap
1.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37M | -11.90M | -27.50% |
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 376.13M |
| UroGen Pharma | 109.79M |
| Septerna | 45.95M |
| uniQure | 16.10M |
| Zenas BioPharma | 10.00M |
| Inventiva | 7.94M |
| Aktis Oncology | 6.50M |
| DBV Technologies | 5.64M |
EYPT News
- 12 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference - Transcripts
- 5 weeks ago - EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
- 7 weeks ago - EyePoint Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 2 months ago - EyePoint Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema - GlobeNewsWire
- 2 months ago - EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 - GlobeNewsWire